Journal of Infection and Chemotherapy最新文献

{"title":"Longitudinal impact of a pharmacist-led stepwise antimicrobial stewardship program on intravenous antimicrobial use at a small resource-limited Japanese hospital","authors":"Yasuhiro Sasaki ,&nbsp;Hiroshi Horiuchi ,&nbsp;Ayumi Umehara ,&nbsp;Masataka Yano ,&nbsp;Yasuaki Tagashira","doi":"10.1016/j.jiac.2025.102697","DOIUrl":"10.1016/j.jiac.2025.102697","url":null,"abstract":"<div><h3>Background</h3><div>Clinical pharmacists play a central role in the implementation of antimicrobial stewardship programs (ASP). However, personnel shortages, the lack of a system for career development, and other challenges impede the active contribution of clinical pharmacists to ASPs in Japan.</div></div><div><h3>Aim</h3><div>To conduct a long-term evaluation of a pharmacist-led antimicrobial stewardship program.</div></div><div><h3>Methods</h3><div>The present, retrospective study used segmented time-series analysis to examine antimicrobial consumption, blood culture practices, and the rate of resistance in pathogens to the antimicrobials prescribed.</div></div><div><h3>Findings</h3><div>After the ASP was introduced, days of therapy (DOT) with anti-pseudomonal agents demonstrated a downward trend (−0.31; 95 % confidence interval [CI]: −0.43 to −0.19; p &lt; 0.01). Moreover, the trend in the number of blood cultures after the intervention significantly increased (0.20; 95 % CI: 0.05 to 0.35; p = 0.01), and the rate of resistance of <em>Pseudomonas aeruginosa</em> to cefepime and piperacillin decreased. No significant change was observed in the DOT trend for total intravenous antimicrobial use before or after the intervention (−1.07; 95 % CI: −2.44 to 0.29; p = 0.12).</div></div><div><h3>Conclusion</h3><div>Although the role of pharmacists in an ASP should continue to be examined, the present, longitudinal study found that stepwise introduction of an ASP reduced broad-spectrum antimicrobial use and was associated with a decrease in the antimicrobial resistance rate of <em>Pseudomonas aeruginosa</em> but not of third-generation cephalosporin-resistant <em>Escherichia coli</em> or MRSA.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102697"},"PeriodicalIF":1.9,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-course treatment for community-acquired pneumonia in adults aged less than 65 years in Japan: A descriptive study using large healthcare claims database","authors":"Mikiyasu Sakai ,&nbsp;Takamasa Sakai ,&nbsp;Fumiko Ohtsu","doi":"10.1016/j.jiac.2025.102698","DOIUrl":"10.1016/j.jiac.2025.102698","url":null,"abstract":"<div><h3>Introduction</h3><div>In community-acquired pneumonia (CAP), short-course treatment is not inferior in effectiveness compared to conventional treatment durations, and clinical guidelines recommend 5–7-day-long treatments. However, it remains unclear how widely this practice is adopted in Japan. This study aimed to clarify the treatment duration of CAP in Japan using a large healthcare claims database.</div></div><div><h3>Methods</h3><div>We used health insurance claims data provided by JMDC Inc. (Tokyo, Japan) and included patients aged 18–64 years diagnosed with CAP who began antibiotic treatment between January 1, 2013, and December 31, 2022. Short-course treatment was defined as ≤ 7 d. Analyses were conducted separately for inpatient and outpatient cases, and the annual trends were also investigated.</div></div><div><h3>Results</h3><div>Overall, 25,572 patients (3367 inpatients and 22,205 outpatients) were included in the analysis. Short-course treatment was administered to 1087 (32 %) inpatients and 15,614 (70 %) outpatients. The proportion of short-course treatments during the 10-year study period was 31–35 % for inpatient cases and 67–72 % for outpatient cases, with no marked changes over the years.</div></div><div><h3>Conclusions</h3><div>The proportion of inpatients receiving short-course treatments for CAP was low. In Japan, especially for inpatient cases, further efforts are required to optimize the duration of CAP treatment.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 5","pages":"Article 102698"},"PeriodicalIF":1.9,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of a flowchart related to achieving the target area under the concentration-time curve for vancomycin: A retrospective multicenter study","authors":"Tomoyuki Ishigo ,&nbsp;Ayako Suzuki ,&nbsp;Yuta Ibe ,&nbsp;Satoshi Fujii ,&nbsp;Masahide Fukudo ,&nbsp;Hiroaki Yoshida ,&nbsp;Hiroaki Tanaka ,&nbsp;Hisato Fujihara ,&nbsp;Fumihiro Yamaguchi ,&nbsp;Fumiya Ebihara ,&nbsp;Takumi Maruyama ,&nbsp;Yusuke Yagi ,&nbsp;Yukihiro Hamada ,&nbsp;Masaru Samura ,&nbsp;Fumio Nagumo ,&nbsp;Toshiaki Komatsu ,&nbsp;Atsushi Tomizawa ,&nbsp;Akitoshi Takuma ,&nbsp;Hiroaki Chiba ,&nbsp;Yoshifumi Nishi ,&nbsp;Kazuaki Matsumoto","doi":"10.1016/j.jiac.2025.102701","DOIUrl":"10.1016/j.jiac.2025.102701","url":null,"abstract":"<div><div>During therapeutic drug monitoring (TDM) for vancomycin (VCM), the area under the concentration-time curve (AUC) is important for balancing efficacy versus toxicity. In a previous study, we developed a decision tree (DT) model to achieve the target AUC during TDM over the follow-up period (AUC_follow-up). This study aimed to validate the DT model for achieving the target AUC_follow-up. Patients who received VCM for at least 72 h and had an initial TDM within four doses between January 2023 and December 2023 were analyzed. The AUC of the initial TDM was calculated over 2-point (peak/trough) concentrations via Bayesian estimation. The target AUC_follow-up was defined as 400–600 μg h/mL.</div><div>Among 188 patients (median age [interquartile range], 66 [56, 79] years; 50 % female), the target AUC_follow-up was achieved in 70 % (132/188). When the predicted AUC was 400–600 μg h/mL, 84 % (102/121) achieved the target AUC_follow-up. In a 12 h dosing interval subgroup, 86 % (88/102) achieved the target AUC_follow-up. Conversely, when the predicted AUC was &lt;400 or &gt;600 μg h/mL, the proportion who achieved the target AUC_follow-up dropped to 44 % (30/67). Only 30 % (3/10) of those with creatinine clearance rates of &gt;130 mL/min/1.73 m² achieved the target. The area under the receiver operating characteristics curve was 0.74, and the R² value was 0.15.</div><div>Our findings confirmed the external validity of the DT model and supported its use for optimizing VCM dosing. Overall, the DT model offers a reliable framework for achieving target AUC values during follow-up for TDM, aiding safe and effective treatment.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 5","pages":"Article 102701"},"PeriodicalIF":1.9,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful detection of an unrecognized outbreak of Mycobacterium tuberculosis in the modern Beijing subfamily through combined molecular epidemiological and population genetic analyses","authors":"Shinichiro Hirai ,&nbsp;Masaki Nakamura ,&nbsp;Satoshi Kawato ,&nbsp;Yushi Hachisu ,&nbsp;Takashi Kikuchi ,&nbsp;Naoshi Ando ,&nbsp;Hiroaki Shigemura ,&nbsp;Nobuhiro Takemae ,&nbsp;Eiji Yokoyama","doi":"10.1016/j.jiac.2025.102700","DOIUrl":"10.1016/j.jiac.2025.102700","url":null,"abstract":"<div><h3>Introduction</h3><div>While multi-locus variable number tandem repeat analysis (MLVA) as molecular epidemiological analysis has been used to detect <em>Mycobacterium tuberculosis</em> outbreaks, its discriminatory power for identifying strains is limited. Whole-genome sequencing (WGS) offers high discriminatory power but is expensive. This study was established to develop a strategy to overcome these limitations of molecular epidemiological analysis by combining it with population genetic analysis.</div></div><div><h3>Methods</h3><div>MLVA data from 2732 <em>M.</em> <em>tuberculosis</em> strains isolated in Chiba Prefecture, Japan, in 2008–2016 were subjected to Bayesian population genetic analysis to subdivide the strains into subfamilies and estimate subpopulations within each subfamily. Annual changes in the number of strains within subpopulations exhibiting linkage disequilibrium (LD) in MLVA data were examined. Only strains from subpopulations displaying significant increases were analyzed by WGS.</div></div><div><h3>Results</h3><div>Significant LD was observed in one subpopulation using Bayesian analysis (designated P3) within the modern Beijing subfamily, which exhibited a significant increase in strain number in 2016. WGS analysis of strains belonging to P3 from 2016 revealed that 17 out of 21 of them differed by three or fewer single-nucleotide polymorphisms from their most similar strain, indicating that they had a common origin (i.e., an outbreak). Among these common-origin strains, one exhibited a four-locus variant in the MLVA, which would not be suspected of being an outbreak-related strain based on MLVA alone without Bayesian analysis.</div></div><div><h3>Conclusion</h3><div>The combination of Bayesian population genetic analysis with MLVA successfully detected <em>M. tuberculosis</em> strains from an unrecognized outbreak by performing WGS on only a subset of the strains.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102700"},"PeriodicalIF":1.9,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143854428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of pain between nasopharyngeal swab collection for influenza PCR testing and pharyngeal image capture for AI-based influenza diagnosis","authors":"Kie Kido ,&nbsp;Takaya Hanawa ,&nbsp;Shinji Kido ,&nbsp;Takahiro Mikawa","doi":"10.1016/j.jiac.2025.102699","DOIUrl":"10.1016/j.jiac.2025.102699","url":null,"abstract":"","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102699"},"PeriodicalIF":1.9,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143843937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Humoral and cellular immune responses to mRNA COVID-19 vaccinations in the elderly: A longitudinal study in Japan","authors":"Kiyoyasu Fukushima ,&nbsp;Toru Kubo ,&nbsp;Yuta Ito ,&nbsp;Yoshie Oda ,&nbsp;Yohsuke Nagayoshi ,&nbsp;Minoru Fukuda ,&nbsp;Takahiro Takazono ,&nbsp;Noriho Sakamoto ,&nbsp;Hiroshi Mukae","doi":"10.1016/j.jiac.2025.102695","DOIUrl":"10.1016/j.jiac.2025.102695","url":null,"abstract":"<div><h3>Objectives</h3><div>This study examined the durability of humoral and cell-mediated immune responses to COVID-19 mRNA vaccines over six months, focusing on age-related changes.</div></div><div><h3>Methods</h3><div>SARS-CoV-2 uninfected Japanese subjects aged 20–99 who received two doses of mRNA COVID-19 vaccine were recruited. SARS-CoV-2 Spike IgG antibody (IgG) level in the serum and the levels of interferon (IFN)-γ in blood stimulated with SARS-CoV-2 specific antigens by QuantiFERON (QFN) SARS-CoV-2 assay were measured.</div></div><div><h3>Results</h3><div>The IgG levels of 138 subjects declined significantly with age and time post-vaccination <em>(p &lt; 0.001).</em> For participants aged 70 and above (n = 80), the IFN-γ levels, an indicator of cell-mediated immunity, also significantly declined over time (p &lt; 0.05). However, in those under 70 (n = 58), the IFN-γ levels were maintained at three- and six months post-vaccination. There was no significant difference in IFN-γ levels between three- and six months post-vaccination for all 138 subjects, including CD4⁺ and CD8⁺ T cell counts. No correlation was observed between IgG antibody levels and secreted IFN-γ values. Multivariate regression analysis revealed a significant correlation between IgG levels and age. In contrast, IFN-γ levels were associated with CD4⁺ T cell counts, CD8⁺ T cell counts, and Performance Status Scores but not with age.</div></div><div><h3>Conclusions</h3><div>The findings suggest that while humoral immunity (IgG levels) decreases with age and time, cell-mediated immunity (IFN-γ levels) is relatively preserved in individuals under 70 up to six months post-vaccination. However, this immune response is significantly attenuated in older adults aged 70 and above, indicating age-related immunosenescence in long-term immunity following COVID-19 vaccination.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 6","pages":"Article 102695"},"PeriodicalIF":1.9,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of Traceable International Standard Materials Using Sequence-Customized Lentivirus, Modeled on SARS-CoV-2 Nucleic Acid Amplification Tests, and Validation through a Pilot External Quality Assessment","authors":"Mizuki Sugawara Itano ,&nbsp;Kotaro Aoki ,&nbsp;Haruka Nakagawa Kamura ,&nbsp;Yoshikazu Ishii ,&nbsp;Kazuhiro Tateda","doi":"10.1016/j.jiac.2025.102694","DOIUrl":"10.1016/j.jiac.2025.102694","url":null,"abstract":"<div><h3>Background</h3><div>International standardization and quality control of nucleic acid amplification tests (NAATs) require traceable, full-process control materials aligned with international standards. We proposed a protocol for producing sequence-customized, traceable full-process controls, validated for stability and utility through a pilot external quality assessment (EQA) using SARS-CoV-2 NAATs as a model.</div></div><div><h3>Methods</h3><div>The concatenated SARS-CoV-2 NAATs target sequence was synthesized as a DNA fragment. A recombinant lentiviral material was generated using the Lentiviral High Titer Packaging Mix (pLVSIN-CMV Neo Vector, Takara Bio). Stability was evaluated after one freeze-thaw cycle at -80°C followed by incubation at 4°C or 25°C for seven days. The reference SARS-CoV-2 reverse transcription-quantitative PCR was standardized internationally using the WHO international standard material (National Institute for Biological Standards and Control). A pilot EQA of SARS-CoV-2 NAAT was conducted in 31 laboratories using high, low, and negative lentiviral materials.</div></div><div><h3>Results</h3><div>The 10⁶-fold dilutions (7.41 x 10³ IU/mL as low-concentration) in 10% FBS/DMEM of the original sequence-customized lentiviral materials were stable for seven days at 4 °C after freeze-thaw. Thirty laboratories reported positive results for high-concentration material, while 27 reported positive results for low-concentration material. GeneXpert (eight laboratories), with Ct values ranging from 22.6-26.7 for high and 32.5-37.0 for low-concentration. One laboratory using FilmArray reported negative results for all materials.</div></div><div><h3>Conclusions</h3><div>The sequence-customized and traceable lentiviral materials demonstrated suitable characteristics for EQA. The EQA results emphasize the importance of NAAT international standardization. These materials would help with NAAT international standardization, internal quality control, and EQA in individual laboratories.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 5","pages":"Article 102694"},"PeriodicalIF":1.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143783797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A questionnaire survey for Japanese parents on intention to vaccinate their children against COVID-19 and influenza","authors":"Taito Kitano ,&nbsp;Takanori Motoki ,&nbsp;Masayuki Onaka ,&nbsp;Masayuki Murata ,&nbsp;Mai Onishi ,&nbsp;Takahiro Mori ,&nbsp;Soshi Hachisuka ,&nbsp;Tenshin Okubo ,&nbsp;Naohiro Yamamoto ,&nbsp;Hiroki Nishikawa ,&nbsp;Rika Suzuki ,&nbsp;Sayaka Yoshida","doi":"10.1016/j.jiac.2025.102693","DOIUrl":"10.1016/j.jiac.2025.102693","url":null,"abstract":"<div><h3>Background</h3><div>Since 2024, coronavirus (COVID-19) and influenza vaccines for children have been voluntarily administered in Japan. Evaluating parental intentions to receive these vaccinations and the reasons for vaccine hesitancy may elucidate issues regarding vaccine confidence. This study aimed to evaluate the intention of parents to vaccinate their children against COVID-19 and influenza.</div></div><div><h3>Methods</h3><div>A questionnaire survey was conducted between July and October 2024. Eligible participants were parents or caregivers of at least one child aged 6 months to 17 years. The questionnaire asked the parents about their intention to vaccinate their children against COVID-19 and influenza for the 2024–2025 season, before and after receiving information about the vaccines, as well as their reasons for not vaccinating.</div></div><div><h3>Results</h3><div>Answers from 213 parents and caregivers of 286 children were included in the study. After reading the vaccine information, 90.1 % of parents intended to vaccinate their children against influenza, while and 9.4 % intended to vaccinate against COVID-19. Of the parents or caregivers, 69.0 % indicated that they would not vaccinate their children with the COVID-19 vaccine, even if it was free. Among those refusing the COVID-19 vaccine, 77.3 % cited safety concerns as the reason for their decision.</div></div><div><h3>Conclusion</h3><div>The intention of parents to vaccinate their children was very high for influenza vaccination. However, only few parents intended to vaccinate their children against the COVID-19 vaccine even after providing medical information. Many parents expressed concerns about the safety of COVID-19 vaccination in children as a reason for not intending to vaccinate.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 5","pages":"Article 102693"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Status of diagnostic test, diagnosis, and treatment of influenza using the national database of health insurance claims and specific health checkups of Japan","authors":"Daisuke Tamura ,&nbsp;Kosuke Iwasaki ,&nbsp;Manami Yoshida ,&nbsp;Yumi Sato ,&nbsp;Shinzo Hiroi ,&nbsp;Eiko Shimizu","doi":"10.1016/j.jiac.2025.102692","DOIUrl":"10.1016/j.jiac.2025.102692","url":null,"abstract":"<div><h3>Background</h3><div>We previously reported the status of diagnostic tests, diagnoses, and prescriptions for influenza in Japan using a large-scale nationwide database, in which the type of health insurance plan was limited and older people were omitted. In this study, we examined the status using a comprehensive Japanese health insurance claims database.</div></div><div><h3>Methods</h3><div>This cross-sectional study used the National Database of Health Insurance Claims and Specific Health Checkups of Japan from April 2009–March 2020. Among the target patients with at least one record of any tests, diagnoses, or prescriptions, the percentages of patients with a combination of tests, diagnoses, and prescriptions were calculated by the influenza season year (SY), demographics, and type of health insurance plan. The percentage of patients diagnosed to those who underwent tests and the percentage of patients who obtained prescriptions to those diagnosed (prescriptions/diagnoses) were calculated according to the medical facility characteristics.</div></div><div><h3>Results</h3><div>The database included 199,964,548 target patients; ≥90 % received either the test alone or test + diagnosis + prescription in SY 2014 and later. The two patterns were predominant at approximately ≥90 % by age in both sexes. Most patients visited medical facilities without beds, where the percentage of prescriptions/diagnoses was 88.1 %.</div></div><div><h3>Conclusions</h3><div>We showed that most patients diagnosed with influenza underwent diagnostic testing and were prescribed antiviral drugs using comprehensive Japanese health insurance claims data. This finding was consistent with our previous study.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 5","pages":"Article 102692"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated brain abscess caused by Aspergillus tubingensis in a patient with alcoholic liver cirrhosis","authors":"Takumi Inaba ,&nbsp;Kensuke Minami ,&nbsp;Haruhiko Ishioka ,&nbsp;Kazumasa Sekiguchi ,&nbsp;Akira Watanabe ,&nbsp;Shuji Hatakeyama","doi":"10.1016/j.jiac.2025.102691","DOIUrl":"10.1016/j.jiac.2025.102691","url":null,"abstract":"<div><div>A 67-year-old Japanese man with alcoholic liver cirrhosis without any other known immunosuppressive conditions presented with a solitary brain abscess caused by <em>Aspergillus tubingensis</em>. <em>A. tubingensis</em>, a cryptic species within the <em>Aspergillus</em> section <em>Nigri</em>, has been reported to exhibit resistance to voriconazole. This case highlights the necessity for considering central nervous system aspergillosis as a differential diagnosis, even in patients without significant immunosuppression. Moreover, molecular identification and antifungal susceptibility testing are crucial for accurate diagnosis and effective management of such infections, as cryptic species within the <em>Aspergillus</em> genus may exhibit varying degrees of resistance to established treatments.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 5","pages":"Article 102691"},"PeriodicalIF":1.9,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143747521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}